Core Insights - Johnson & Johnson has launched a direct-to-consumer website named J&J Direct to sell certain medications directly to U.S. patients without insurance or those paying out of pocket [1] - The website currently lists three drugs: diabetes treatments Invokana and Invokamet, and blood thinner Xarelto [1] - This initiative is part of a broader commitment by the company to enhance access to its drugs, following an agreement with the Trump administration aimed at reducing drug prices [1] Business - The company has pledged to invest $55 billion in the U.S. over four years as part of its strategy to improve drug accessibility [1] - Johnson & Johnson is among several pharmaceutical companies, including Pfizer and Eli Lilly, that have initiated direct-to-consumer sales platforms [1] - The U.S. government has also launched TrumpRx.gov, a website offering discounted prescription medicines, although Johnson & Johnson is not currently selling on this platform [1]

2,750,909+$14.31+7.24%$211.95DatadogDDOG• Vol: 1,977,324+$7.56+6.76%$119.33## Top Losing StocksCloroxCLX• Vol: 822,230-$4.413.64%$116.75APAAPA• Vol: 1,880,998-$1.043.27%$30.81Constellation BrandsSTZ• Vol: 631,483-$4.783.06%$151.24AmcorAMCR• Vol: 1,214,898-$1.342.83%$45.84Baker HughesBKR• Vol: 3,281,027-$1.752.80%$60.79 Top 3 Dividend Aristocrat Stocks to Buy for Strong Returns in 2026 - 24/7 Wall St.S&P 5006,866.60 +0.86%Dow Jones48,771.60 +0.69%Nasdaq 10025,074.00 +1.57%Russell 20002,633.68 +1.09%FTSE 1001 ...

【兴证医药】强生发布KLK2 TCE Pasritamig联合多西他赛mCRPC数据 安全性:≥3 TRAE 27.5%（pasr 安全性:≥3 TRAE 27.5%（pasritamig相关2.0%），未出现任何等级的CRS，展现了突出的安全性优势。 【兴证医药】强生发布KLK2 TCE Pasritamig联合多西他赛mCRPC数据 国内前列腺癌TCE布局: 复宏汉霖HLX3902(CD3/STEAP1/CD28，临床前) ，岸迈生物EM1031(CD3/KLK2，授权至JuriBiosciences) 患者基线:共入组51例中位3线mCRPC患者，其中43.1%多西他赛经治，19.6%Pluvicto经治疗 患者基线:共入组51例中位3线mCRPC患者，其中43.1%多西他赛经治，19.6%Pluvicto经治疗 有效性:全体人群中PSA50 64.7%，PSA90 35.3%; 紫杉烷类未经治患者PSA50 75.0%，PSA90 46.4%。 有效性:全体人群中PSA50 64.7%，PSA90 35.3%; 紫杉烷类未经治患者PSA50 75.0%，PSA90 46.4%。 ...

Question-and-Answer SessionJoshua JenningsTD Cowen, Research Division Absolutely. We're going to focus a little bit on the high-level strategy and the MedTech franchise. That's our wheelhouse. I know you guys have a much bigger wheelhouse with the pharma unit. It's been an incredible stock performance year in 2025 for Johnson & Johnson, and a lot of that was driven by both MedTech and Innovative Medicines, but Innovative Medicines is kind of battling through. The STELARA LOE headwind was quite impressive, a ...

Johnson & Johnson (NYSE: JNJ) FY Conference Summary Company Overview - **Company**: Johnson & Johnson - **Date of Conference**: March 03, 2026 - **Key Speaker**: Joe Wolk, Executive Vice President and CFO Core Industry Insights Pharmaceutical Sector - **STELARA Loss of Exclusivity**: The company successfully navigated the loss of exclusivity for STELARA, which was anticipated and managed effectively, leading to a growth of nearly 15% in the pharmaceutical business when excluding the impact of STELARA [14][15] - **Historical Context**: Johnson & Johnson has previously overcome similar challenges, such as with REMICADE in 2018, demonstrating resilience in its pharmaceutical portfolio [14] MedTech Sector - **Acquisitions**: Strategic acquisitions of Abiomed and Shockwave have strengthened the cardiovascular franchise, leading to more predictable growth in the MedTech sector [14][19] - **Separation of Orthopaedics**: The decision to separate the orthopaedics business is aimed at focusing on higher growth and higher margin businesses, which is expected to enhance overall portfolio performance [15][35] Financial Performance and Projections - **Stock Performance**: The stock had a strong performance in 2025, attributed to both the MedTech and Innovative Medicine sectors [8][10] - **Growth Targets**: The company is targeting double-digit growth as an enterprise moving forward, with expectations of improved performance in 2026 [16][30] - **MedTech Growth Rate**: Current growth for the MedTech unit is projected at 5%-7%, with potential to exceed this range post-orthopaedic separation [30][35] Product and Innovation Highlights Vision and Surgery - **Vision Market**: The company holds a leadership position in contact lenses, with significant opportunities for growth as only 10% of those needing corrective lenses currently use contact lenses [20] - **Surgery Innovations**: The launch of new products like TECNIS and PureC is expected to drive growth in the surgery segment, particularly for cataract procedures [21] Electrophysiology - **Pulsed Field Ablation (PFA)**: The company is focusing on improving its PFA platform, which faced initial challenges but is expected to perform better in 2026 [45][46] - **CARTO System**: The CARTO mapping system is considered the gold standard, with ongoing innovations expected to enhance its capabilities and maintain market leadership [65][66] Strategic Initiatives - **M&A Strategy**: Johnson & Johnson's approach to mergers and acquisitions is opportunistic, focusing on strategic fit and scientific capabilities rather than market timing [37][38] - **Portfolio Management**: The company has been active in optimizing its portfolio, having deployed approximately $56 billion in capital on acquisitions over the past three years [41][42] Operational Considerations - **Cost Structure**: The separation of the orthopaedics business is expected to help streamline operations and reduce stranded costs, contributing to margin improvements [93][99] - **Operating Margin Guidance**: The company anticipates at least a 50 basis point improvement in pre-tax margins for 2026, driven by revenue growth and cost management [96][99] Other Notable Points - **Geopolitical Impact**: The ongoing conflict in the Middle East has not significantly impacted the company's operations, thanks to its geographical diversity and focus on employee safety [61][62] - **Future Outlook**: The company is optimistic about its growth trajectory, with a focus on ensuring successful product launches and maintaining market leadership across its franchises [80][82]

Retire Comfortably With These Dividend Growth Stocks - 24/7 Wall St.[S&P 5006,756.40 -1.73%][Dow Jones47,912.40 -1.94%][Nasdaq 10024,526.80 -1.74%][Russell 20002,578.94 -2.71%][FTSE 10010,476.60 -3.01%][Nikkei 22554,336.20 -5.55%][Stock Market Live March 3, 2026: S&P 500 (SPY) Down Big on Iran War Fears][Investing]# Retire Comfortably With These Dividend Growth Stocks### Quick ReadGoldman Sachs (GS) more than tripled its dividend distributions over the past five years.Lowe's (LOW) has doubled its dividend p ...

Key Takeaways J&J's immunology sales fell 12% in 2025 as Stelara dropped 42% after losing exclusivity.J&J saw Tremfya sales jump 41% to over $5B, while Simponi rose 22% to $2.7B.J&J's neuroscience sales climbed 10%, with Spravato up 57% and Caplyta reaching $700M.Johnson & Johnson (JNJ) is one of the key pharmaceutical players in the oncology segment, with its Oncology segment comprising around 27% of total revenues and 42% of its Innovative Medicine segment sales. However, J&J also boasts a strong presence ...

Core Insights - Johnson & Johnson's therapy nipocalimab has received U.S. FDA Fast Track designation for systemic lupus erythematosus (SLE), highlighting the unmet need in this serious disease and enabling a potentially accelerated review timeline [1][2] - The Fast Track designation is supported by a Phase 2 study showing nipocalimab's effectiveness in reducing lupus disease activity and its potential for steroid-sparing effects [1][2] - Johnson & Johnson is currently enrolling patients for a Phase 3 study of nipocalimab in adults with active SLE, indicating ongoing commitment to addressing this debilitating condition [1] Company Overview - Johnson & Johnson is focused on healthcare innovation, aiming to develop treatments that are smarter and less invasive, with a commitment to addressing complex diseases [2] - The company has a strong pipeline for nipocalimab, which has received multiple FDA designations across various conditions, including Priority Review and Breakthrough Therapy designations [2] Disease Context - Systemic lupus erythematosus affects approximately 3 to 5 million people globally, with a significant impact on quality of life due to chronic symptoms and the risk of irreversible organ damage [1][2] - The disease predominantly affects women, with a ratio of nine women to one man, often beginning between the ages of 15 and 44 [1][2] Clinical Development - The Phase 2b JASMINE study demonstrated positive results, leading to the initiation of the Phase 3 GARDENIA study for adults with active SLE [1] - Nipocalimab is the only FcRn blocker to show a reduction in SLE disease activity, marking a significant advancement in treatment options for this condition [1]

来源：滚动播报 美国银行全球研究部将强生公司目标股价从227美元上调至253美元。 ...

For years of working with organizations to refine and implement vision and core values, I’ve told the Johnson & Johnson Tylenol story. You’ve probably heard it.In 1982, seven people in the Chicago area mysteriously died after consuming Tylenol. An investigation quickly revealed the victims’ capsules had been laced with cyanide, with no indication of how widespread the threat was.The manufacturer of Tylenol, the legendary company Johnson & Johnson, took no chance. They pulled 31 million bottles off shelves, ...